Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a novel, once-monthly RNA-targeted therapy for familial chylomicronemia syndrome (FCS).
The drug enters the market at an annual list price of $595,000, following its FDA approval in December 2024.
First FDA-Approved Olezarsen Therapy for...
Below is a detailed description of the mechanism of action and dosage of PARSABIV (Etelcalcetide Hydrochloride Injection):
Mechanism of Action
PARSABIV is a synthetic calcimimetic peptide drug. Its active ingredient, etelcalcetide, specifically binds to and activates the calcium-sensing receptors (CaSR) on the surface of parathyroid cells. By mimicking the physiological effects of increased...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Portuguese (Brazil)
Greek
